Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
Want to see ENTA full AI Analyst Report?
Top Page
Enanta Pharmaceuticals
(NASDAQ:ENTA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$13.00
▼(-7.21% Downside)
Action:Reiterated
Date:05/18/26
The score is primarily held back by weak financial performance: persistent losses, negative cash flow, and still-elevated leverage despite some improvement. Technicals show soft near-term momentum with some potentially oversold signals, while valuation remains challenged due to a loss-making profile and no dividend yield. Corporate events are mildly supportive on governance but include potential dilution from the equity plan expansion.
Positive Factors
Collaboration-driven revenue model
A revenue model built on collaboration, upfronts, milestones and royalties provides diversified, non-dilutive funding to support R&D and operations. These partner-derived cash flows are durable income sources that reduce sole reliance on internal commercialization for near- to mid-term sustainability.
Negative Factors
Persistent negative cash flow
Ongoing negative operating and free cash flow is a structural constraint: even with improvement, the company must secure external funding, partner milestone timing, or commercial launches to sustain R&D. Persistent burn limits strategic optionality and increases financing and dilution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Collaboration-driven revenue model
A revenue model built on collaboration, upfronts, milestones and royalties provides diversified, non-dilutive funding to support R&D and operations. These partner-derived cash flows are durable income sources that reduce sole reliance on internal commercialization for near- to mid-term sustainability.
Read all positive factors
Enanta Pharmaceuticals (ENTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$389.94M
Dividend YieldN/A
Average Volume (3M)132.86K
Price to Earnings (P/E)―
Beta (1Y)1.60
Revenue Growth7.37%
EPS Growth42.85%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.74
Shares Outstanding29,078,380
10 Day Avg. Volume111,827
30 Day Avg. Volume132,863
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.95
Price to Sales (P/S)3.91
P/FCF Ratio-7.94
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue6.70
Enterprise Value/Gross Profit13.87
Enterprise Value/Ebitda-9.31
Forecast
1Y Price Target
$19.67Price Target Upside40.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.26
Revenue Forecast (FY)$68.02M
Enanta Pharmaceuticals Business Overview & Revenue Model
Company Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV...
How the Company Makes Money
Enanta primarily makes money through (1) collaboration and licensing revenue and (2) potential future product revenue if it commercializes any of its wholly owned drug candidates. Collaboration/licensing revenue is generated by granting partners r...
Enanta Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 06, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Aug 10, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed sentiment with significant advancements in the RSV and immunology programs and a stable financial position. However, it also highlighted challenges with a decline in revenue, increased net loss, and slower enrollment in the RSVPEDs study.Positive Updates
RSV Program Advancements
Progress in developing the first oral antiviral treatment for RSV, with two Phase II studies (RSVPEDs and RSVHR) ongoing and anticipation of reporting data in the second half of 2024.
Negative Updates
Revenue Decline
Total revenue for the quarter decreased to $17.1 million from $17.8 million in the same period in 2023, primarily due to lower royalty rates.
Read all updates
Q2-2024 Updates
Positive
Negative
RSV Program Advancements
Progress in developing the first oral antiviral treatment for RSV, with two Phase II studies (RSVPEDs and RSVHR) ongoing and anticipation of reporting data in the second half of 2024.
Read all positive updates
Company Guidance
During the earnings call for Enanta Pharmaceuticals' fiscal second quarter of 2024, the company provided guidance on several key metrics. For the quarter, total revenue was reported at $17.1 million, primarily from royalty revenue tied to AbbVie's MAVYRET sales. The company updated its expense guidance, projecting research and development expenses to range between $125 million and $145 million, reflecting increased investment in its RSV and new immunology programs. General and administrative expenses are expected to be between $50 million and $60 million, influenced by additional stock compensation and legal costs. Enanta concluded the quarter with approximately $300 million in cash and marketable securities, anticipating this will support its existing operations through the third quarter of fiscal 2027. The company is also advancing its RSV and CSU programs, with milestones including data readouts expected in the second half of 2024 and the introduction of a second immunology program.Enanta Pharmaceuticals Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
38
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 69.21M | 65.32M | 67.64M | 79.20M | 86.16M | 97.07M |
| Gross Profit | 33.44M | 60.74M | 67.64M | 79.20M | 86.16M | 97.07M |
| EBITDA | -49.85M | -70.78M | -104.51M | -123.48M | -119.22M | -104.25M |
| Net Income | -61.98M | -81.89M | -116.05M | -133.82M | -121.75M | -79.00M |
Balance Sheet | ||||||
| Total Assets | 314.70M | 280.73M | 376.65M | 462.27M | 380.59M | 440.86M |
| Cash, Cash Equivalents and Short-Term Investments | 163.77M | 188.86M | 248.19M | 369.91M | 249.23M | 244.00M |
| Total Debt | 186.62M | 201.06M | 226.06M | 222.44M | 26.69M | 6.83M |
| Total Liabilities | 198.12M | 216.01M | 247.84M | 245.54M | 59.26M | 41.43M |
| Stockholders Equity | 116.59M | 64.72M | 128.81M | 216.74M | 321.33M | 399.43M |
Cash Flow | ||||||
| Free Cash Flow | -9.61M | -32.17M | -96.71M | -112.21M | -86.91M | -70.75M |
| Operating Cash Flow | -7.84M | -19.27M | -78.76M | -103.15M | -84.78M | -70.00M |
| Investing Cash Flow | -59.54M | 40.35M | 58.23M | -53.58M | 54.90M | 36.99M |
| Financing Cash Flow | 42.10M | -26.62M | -27.63M | 198.13M | 20.03M | 3.08M |
Enanta Pharmaceuticals Technical Analysis
Positive
14.01
Price Trends
13.60
Positive
13.82
Positive
11.50
Positive
Market Momentum
0.27
Negative
55.97
Neutral
67.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTA, the sentiment is Positive. The current price of 14.01 is above the 20-day moving average (MA) of 13.25, above the 50-day MA of 13.60, and above the 200-day MA of 11.50, indicating a bullish trend. The MACD of 0.27 indicates Negative momentum. The RSI at 55.97 is Neutral, neither overbought nor oversold. The STOCH value of 67.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ENTA.
Enanta Pharmaceuticals Risk Analysis
Enanta Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Enanta Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Enanta Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $312.90M | -3.71 | 41.40% | ― | ― | ― | |
55 Neutral | $1.15B | -5.03 | -51.34% | 14.68% | ― | 94.97% | |
52 Neutral | $690.31M | -3.44 | -57.07% | ― | ― | 37.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $526.26M | -5.75 | -32.33% | ― | ― | 38.99% | |
49 Neutral | $340.92M | -1.64 | -181.70% | ― | ― | 17.61% | |
45 Neutral | $389.94M | -6.97 | -64.04% | ― | 7.37% | 42.85% |
* Healthcare Sector Average
ENTA
Enanta Pharmaceuticals
13.45
7.49
125.67%
ABEO
Abeona Therapeutics
5.37
-0.86
-13.80%
TECX
Tectonic Therapeutic
27.70
4.29
18.33%
ALLO
Allogene Therapeutics
1.94
0.85
77.98%
JBIO
Jade Biosciences
22.01
14.59
196.63%
NMRA
Neumora Therapeutics, Inc.
1.77
1.08
156.52%
Enanta Pharmaceuticals Corporate Events
Business Operations and StrategyLegal Proceedings
Enanta Advances Federal Circuit Appeal in Paxlovid Patent Case
Neutral
Mar 26, 2026
Enanta Pharmaceuticals, Inc., a biotechnology company specializing in small-molecule antiviral therapies, is pursuing litigation to protect its intellectual property related to COVID-19 treatments. The company has alleged that Pfizer’s COVID...
Executive/Board ChangesShareholder Meetings
Enanta Shareholders Approve Board Elections and Equity Plan
Positive
Mar 12, 2026
At its annual meeting on March 11, 2026, Enanta Pharmaceuticals’ shareholders re-elected Bruce L.A. Carter, Ph.D., and Jay R. Luly, Ph.D., as Class I directors to serve until the 2029 annual meeting, reinforcing continuity in the companyR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.